China’s blue-chip CSI300 Index has dropped to nine-month lows, and is down 11% from an April peak

A fresh crackdown on the country's medical and pharmaceutical sectors, set to last a year, has convinced investors that it may be best to buy the state and sell private sector holdings

Recent net selling of Chinese equities was the largest over any 10-day period since October 2022 and one of the steepest moves in the past five years

Goldman Sachs analysts project a 15% 12-month return for the CSI300, which is now down 0.5% for the year, in stark contrast to the 16% rise in world stocks.

After a smaller-than-expected interest rate cut raised doubts on whether Chinese policymakers would act forcefully enough to support the economy, investors are positioning for a longer game

The move is China's latest effort to enable the internationalisation of the yuan and protect its economy from capital outflows and geopolitical risks

The Nasdaq Golden Dragon China Index of New York-listed mainland companies, consisting mainly of internet giants such as Alibaba Group, Baidu.com and JD.com, lost 5.6% this month

Stocks of China's semiconductor companies have seen large gains since March with NAURA Technology Group up 14%, Piotech up 45% and ACM Research Shanghai up 19%

The sale is part of a series of similar moves by Berkshire, which started selling its BYD shares in late August last year

At least one WeChat group with several hundred members has been formed by anxious Chinese clients of SVB seeking to safeguard their interest

Chinese firms raised $71.2 billion, putting them far ahead of the $17.3 billion raised by US companies' listings and European firms' $16.4 billion from IPOs this year

Criminals also try to entice people to invest in these IPOs through texting, social media and sometimes even seemingly misdirected messages